IN8bio (INAB) CEO receives 206,000 stock options at $1.96

Rhea-AI Filing Summary

IN8bio, Inc. (INAB) reported a new stock option grant to CEO, director and 10% owner William Tai-Wei Ho. On February 4, 2026, he received an employee stock option covering 206,000 shares of common stock at an exercise price of $1.96 per share, expiring February 4, 2036.

According to the vesting terms, 25% of the option shares vest on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, as long as he continues to provide service through each vesting date. Following this grant, he beneficially owns 206,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ho William Tai-Wei

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	206,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 206,000 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ho William Tai-Wei

(Last) (First) (Middle)

C/O IN8BIO, INC.

350 5TH AVE. SUITE 5330

(Street)

NEW YORK NY 10118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.96	02/04/2026		A		206,000		(1)	02/04/2036	Common Stock	206,000	$0	206,000	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

	/s/ William Ho	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IN8bio (INAB) report for William Ho?

IN8bio reported a new stock option grant to CEO William Tai-Wei Ho for 206,000 shares of common stock at a $1.96 exercise price. The option was granted on February 4, 2026 and expires on February 4, 2036, subject to the stated vesting schedule.

How many IN8bio (INAB) stock options were granted to the CEO?

The CEO, William Tai-Wei Ho, was granted employee stock options covering 206,000 shares of IN8bio common stock. These options are exercisable at $1.96 per share and expire on February 4, 2036, with vesting over several years based on continued service.

What is the vesting schedule for William Ho’s IN8bio stock options?

Twenty-five percent of the option shares vest on February 4, 2027. The remaining shares vest in thirty-six equal monthly installments after that date, provided William Ho continues to provide service to the company through each monthly vesting date.

What is the exercise price and expiration date of IN8bio CEO’s options?

The employee stock options granted to IN8bio CEO William Ho have an exercise price of $1.96 per share. They expire on February 4, 2036, giving a ten-year term from the grant date, subject to the vesting conditions described in the footnote.

How many derivative securities does William Ho own after this IN8bio grant?

After the reported grant, William Tai-Wei Ho beneficially owns 206,000 derivative securities in the form of employee stock options. These options are held directly, relate to IN8bio common stock, and are subject to the specified vesting and expiration terms.